Please login to the form below

Not currently logged in
Email:
Password:

Acorda Therapeutics appoints chief medical officer

Interim CMO Dr Burkhard Blank takes on the post in a permanent capacity

New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer.

Dr Blank has served in the role in a temporary capacity since January this year and now takes on the post permanently.

He brings over 25 years of industry experience to Acorda, and has held senior leadership positions at Altus Pharmaceuticals, Herantis Pharma and Laurantis Pharma.

Prior to this, Dr Blank worked at Boehringer Ingelheim, first as its global head for regulatory affairs before serving as its chief medical officer between 2001 and 2006.

Dr Ron Cohen, president and chief executive of Acorda, said: “I am delighted that Burkhard has joined Acorda as our chief medical officer.

“Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs. This will benefit Acorda's entire pipeline, including our late-stage development programs, CVT-301 and tozadenant for Parkinson's disease.”

5th July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...